04252018Headline:

Dallas-Fort Worth, Texas

HomeTexasDallas-Fort Worth

Email Shezad Malik MD JD Shezad Malik MD JD on LinkedIn Shezad Malik MD JD on Twitter Shezad Malik MD JD on Facebook Shezad Malik MD JD on Avvo
Shezad Malik MD JD
Shezad Malik MD JD
Attorney • (888) 210-9693

Onglyza blamed for woman’s heart failure

0 comments

Onglyza blamed for woman’s heart failure. Cathy Nelson, from Kentucky, claims that she developed, congestive heart failure and cardiovascular injury, from the use of a popular type 2 diabetic medication Onglyza.

Onglyza blamed for woman's heart failure

Onglyza blamed for woman’s heart failure. Cathy Nelson, from Kentucky, claims that she developed, congestive heart failure and cardiovascular injury, from the use of a popular type 2 diabetic medication Onglyza.

Cathy Nelson filed her personal injury and product liability lawsuit in the U.S. District Court for the Southern District of New York blaming Bristol-Myers Squibb, AstraZeneca, and McKesson Corporation for her injuries.

Nelson took Onglyza and Kombiglyze XR from about two years when she was diagnosed with signs and symptoms of heart failure requiring hospitalization.

According to Nelson, the companies were derelict in their duty to warn patients and doctors about the heart risks with Onglyza and Kombiglyze XR.

What is Onglyza?

Onglyza (saxagliptin) is made by AstraZeneca and Bristol Myers Squibb and approved for release in 2009 for treatment of type 2 diabetes. Kombilgyze XR is an extended release version combining saxagliptin with the older diabetes drug metformin.

Onglyza belongs to a new class of diabetic drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors.

According to experts and medical studies which warn about Onglyza heart failure risks, and in 2017 the FDA ordered stronger heart failure warning labels.

FDA Investigation into Onglyza Heat Failure Side Effects

The FDA launched an investigation of heart failure risks with Onglyza in 2014, after the SAVOR study, published in the New England Journal of Medicine in 2013.

In April 2015, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended stronger warnings about the increased risk of Onglyza heart failure side effects after reviewing data from two large clinical trials.

The two large clinical trials found that diabetic patients taking saxagliptin or alogliptin were at a higher risk of being hospitalized for heart failure than those given a placebo or a sugar pill.

The FDA added Heart Failure warnings for Onglyza in April 2016. The FDA also has urged patients and healthcare professionals to report Onglyza heart failure side effects to the FDA MedWatch program.

Onglyza Multidistrict Litigation

In February, the U.S. Judicial Panel on Multidistrict Litigation centralized and consolidated all federal Onglyza cases in the U.S. District Court for the Eastern District of Kentucky, as part of a federal MDL, or multidistrict litigation, under District Judge Karen K. Caldwell.

If you or a loved one has taken Onglyza and suffered heart failure and/or death, you may have an injury claim against AstraZeneca. To learn more about your legal rights, call Dr. Shezad Malik Law Firm at 888-210-9693 for a free case review. Dr. Shezad Malik Law Firm is based in Dallas, Texas and is investigating and accepting Onglyza Heart Failure injuries nationwide.

Read more about Onglyza here

Texas Onglyza Heart Failure Attorney

Onglyza Heart Failure Injuries Lawsuits Centralized

Leave a Comment

Have an opinion? Please leave a comment using the box below.

For information on acceptable commenting practices, please visit Lifehacker's guide to weblog comments. Comments containing spam or profanity will be filtered or deleted.